QIAGEN and Celera Establish Distribution Agreement for Respiratory Pathogen Panel

(Thomson Reuters ONE) - Qiagen N.V. / QIAGEN and Celera Establish Distribution Agreement for Respiratory Pathogen Panel processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. VENLO, The Netherlands, and ALAMEDA, California -February 11, 2010 - QIAGEN N.V.(NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and Celera Corporation(NASDAQ:CRA) today announced an agreement under which QIAGEN will distribute aCelera molecular multiplex assay. The assay is the next generation version ofQIAGEN's ResPlex II assay for detection of respiratory pathogens. Multiplexassays allow testing for a multiple number of different pathogens in a singlerun. Financial details were not disclosed.Under the terms of the agreement, QIAGEN has the exclusive worldwide rights todistribute this multiplex test kit, which will be manufactured by Celera. Thenew ResPlex assay detects 19 different pathogens associated with respiratoryinfections and is designed for use with LiquiChip (Luminex) 100 and 200instrument platforms."Celera's significant experience in the development and manufacturing ofmolecular diagnostic products is a very valuable resource and this relationshipcan accelerate our effort to further expand our molecular diagnostic solutionportfolio," said Peer Schatz, CEO of QIAGEN. "We believe that this new producthas the potential to provide significant value for laboratories, healthcareprofessionals and patients worldwide.""We are pleased to have entered into this agreement with QIAGEN as we looktoward the development and marketing of a molecular diagnostic solution toaddress certain infectious respiratory diseases and provide our customers with aproduct of the highest quality," said Kathy Ordo? CEO of Celera.The new ResPlex kits will be available through QIAGEN's existing sales channels.The new test will be submitted for regulatory approval in the United States andEurope.About QIAGEN:QIAGEN N.V., a Netherlands holding company, is the leading global provider ofsample and assay technologies. Sample technologies are used to isolate andprocess DNA, RNA and proteins from biological samples such as blood ortissue. Assay technologies are used to make such isolated bio-molecules visible.QIAGEN has developed and markets more than 500 sample and assay products as wellas automated solutions for such consumables. The company provides its productsto molecular diagnostics laboratories, academic researchers, pharmaceutical andbiotechnology companies, and applied testing customers for purposes such asforensics, animal or food testing and pharmaceutical process control. QIAGEN'sassay technologies include one of the broadest panels of molecular diagnostictests available worldwide. This panel includes the digene HPV Test, which isregarded as a "gold standard" in testing for high-risk types of humanpapillomavirus (HPV), the primary cause of cervical cancer, as well as a broadsuite of solutions for infectious disease testing and companion diagnostics.QIAGEN employs more than 3,500 people in over 30 locations worldwide. Furtherinformation about QIAGEN can be found at http://www.qiagen.com/.QIAGENSAFE HARBOR STATEMENTStatements contained in this release that are not historical facts areforward-looking statements, including statements about the new molecularmultiplex assay and our products, markets and strategy. Such statements arebased on current expectations that involve risks and uncertainties including,but not limited to, those associated with: management of growth andinternational operations (including currency fluctuations and logistics),variability of our operating results, commercial development of our markets(including applied testing, clinical and academic research, proteomics, women'shealth/HPV testing, molecular diagnostics, personalized healthcare and companiondiagnostics), our relationships with customers, suppliers and strategicpartners, competition, changes in technology, fluctuations in demand, regulatoryrequirements, identifying, developing and producing integrated productsdifferentiated from our competitors' products, market acceptance of ourproducts, and integration of acquired technologies and businesses. For furtherinformation, refer to our filings with the SEC, including our latest Form 20-F.Information in this release is as of the date of the release, and we undertakeno duty to update this information unless required by law.About Celera:Celera is a healthcare business focusing on the integration of genetic testinginto routine clinical care through a combination of products and servicesincorporating proprietary discoveries. Berkeley HeartLab, a subsidiary ofCelera, offers services to predict cardiovascular disease risk and improvepatient management. Celera also commercializes a wide range of moleculardiagnostic products throughAbbott and has licensed other relevant diagnostictechnologies developed to provide personalized disease management in cancer.Information about Celera Corporation, including reports and other informationfiled by the company with the Securities and Exchange Commission, is availableat http://www.celera.com .Celera Forward-Looking StatementsCertain statements in this press release are forward-looking. These may beidentified by the use of forward-looking words or phrases such as "believe,""expect," "will," "should," "anticipate," "may," "could," and "intend," amongothers. These forward-looking statements are based on Celera's currentexpectations. The Private Securities Litigation Reform Act of 1995 provides a"safe harbor" for such forward-looking statements. In order to comply with theterms of the safe harbor, Celera notes that a variety of factors could causeactual results and experience to differ materially from the anticipated resultsor other expectations expressed in such forward-looking statements. The risksand uncertainties that may affect the operations, performance, development, andresults of our business include, but are not limited to, the risks anduncertainties that: (1) the agreement with QIAGEN may be terminated; (2) therisk that the products contemplated by this agreement will not receiveregulatory approvals; and (3) the uncertainty that any products will be acceptedand adopted by the market, including the risk that that these products will notbe competitive with tests offered by other companies. The foregoing list setsforth some, but not all, of the factors that could affect Celera's ability toachieve results described in any forward-looking statements. For additionalinformation about the risks and uncertainties that Celera faces and a discussionof its financial statements and footnotes, see documents filed by Celera withthe SEC, including its transition report on Form 10-KT and all subsequentperiodic reports. All information in this press release is as of the date of therelease, and Celera does not undertake any duty to update this information,including any forward-looking statements, unless required by law. # # #Contacts: Investor Relations: Public Relations: Dr. Solveigh M?er Dr. Thomas Theuringer Director Investor Relations Associate Director Public Relations QIAGEN N.V. QIAGEN GmbH +49 2103 29 11710 +49 2103 29 11826 e-mail:solveigh.maehler(at)qiagen.com e-mail:thomas.theuringer(at)qiagen.com Albert F. Fleury Celera: Investor Relations North America Dr. David Speechly QIAGEN N.V. +1 510 749-1853 +1 301 944 7028 e-mail:David.Speechly(at)Celera.com e-mail:albert.fleury(at)qiagen.com [HUG#1383314] --- End of Message --- Qiagen N.V.Spoorstraat 50 KJ Venlo NetherlandsWKN: 901626;ISIN: NL0000240000;Index:Prime All Share,TecDAX,HDAX,MIDCAP;TECH All Share;

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Leseranfragen:
PresseKontakt / Agentur:
Bereitgestellt von Benutzer: hugin
Datum: 11.02.2010 - 02:30 Uhr
Sprache: Deutsch
News-ID 1010247
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

KJ Venlo

Phone:

Kategorie:

Business News

Anmerkungen:


Diese Pressemitteilung wurde bisher 98 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"QIAGEN and Celera Establish Distribution Agreement for Respiratory Pathogen Panel
"
steht unter der journalistisch-redaktionellen Verantwortung von

Qiagen N.V. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Alle Meldungen von Qiagen N.V.